Envista Holdings (NVST) AI Stock Analysis

• Market Cap: $3.30B
• Dividend Yield: N/A
• Average Volume (3M): 2.22M
• Price to Earnings (P/E): 241.7
• Beta (1Y): 0.98
• Revenue Growth: 4.73%
• EPS Growth: N/A
• Country: US
• Employees: 12,300
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Equipment & Services
• EPS (TTM): 0.32
• Shares Outstanding: 164,426,240
• 10 Day Avg. Volume: 2,894,615
• 30 Day Avg. Volume: 2,216,926
• PEG Ratio: >-0.01
• Price to Book (P/B): 1.13
• Price to Sales (P/S): 1.32
• P/FCF Ratio: 10.97
• Enterprise Value/Market Cap: 1.17
• Enterprise Value/Revenue: 1.47
• Enterprise Value/Gross Profit: 2.65
• Enterprise Value/Ebitda: 10.46
• 1Y Price Target: $22.38
• Price Target Upside: 11.62% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 11
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 64 Neutral
• Price Target: $21.50 ▲(7.23% Upside)

Envista Holdings' overall stock score is driven by strong earnings call performance and stable financials, despite high valuation concerns. The company's raised guidance and operational improvements are positive, but the high P/E ratio and market uncertainties, particularly in China, pose risks.

Positive Factors

Revenue Growth

The revised revenue growth guidance indicates strong market demand and effective strategic initiatives, suggesting sustained business expansion.

Geographic and Segment Expansion

Expansion in emerging markets enhances Envista's global footprint and diversifies revenue streams, reducing reliance on mature markets.

Innovation and M&A

Strategic acquisitions and product launches strengthen Envista's competitive position and foster long-term growth through innovation.

Negative Factors

Free Cash Flow Decline

Declining free cash flow can limit Envista's ability to invest in growth opportunities and may signal operational inefficiencies.

Profitability Concerns

Low net profit margins indicate challenges in converting revenue into profit, potentially impacting long-term financial health.

Challenges in China

Declines in China, a key market, could hinder overall growth and reflect broader challenges in adapting to local regulatory changes.

Envista Holdings Business Overview & Revenue Model

Company Description

Envista Holdings Corporation (NVST) is a global leader in dental products and technologies, focused on delivering innovative solutions that enhance the productivity and efficiency of dental professionals. The company operates primarily in the dental and orthodontics sectors, offering a wide range of products including dental equipment, consumables, and digital solutions. Envista's portfolio includes well-known brands such as KaVo, Kerr, and Ormco, which cater to various aspects of dental care, from restorative and orthodontic treatments to imaging and practice management software.

How the Company Makes Money

Envista Holdings generates revenue through multiple streams, primarily by selling dental products and technologies to dental professionals, laboratories, and healthcare providers. The company's revenue model encompasses both direct sales of its products and services, as well as recurring revenue from consumables used in dental procedures. Key revenue streams include the sale of dental equipment (like imaging systems and treatment units), dental consumables (such as restorative materials and orthodontic products), and digital solutions that aid in practice management and patient care. Additionally, Envista has strategic partnerships with dental practices and organizations, which enhance its market reach and contribute to its earnings through collaborative initiatives and bundled offerings.

Envista Holdings Financial Statement Overview

Summary

Envista Holdings exhibits a stable financial position with moderate growth and profitability. The income statement reflects steady revenue growth but challenges in profit conversion. The balance sheet is robust with a balanced debt-to-equity ratio, while cash flow metrics show effective cash generation. Overall, the company is positioned for growth but needs to enhance profitability and operational efficiency to maximize shareholder value.

Income Statement

Envista Holdings shows a modest revenue growth rate of 2.7% TTM, indicating a positive trajectory compared to the previous year. However, the net profit margin remains low at 0.58% TTM, reflecting challenges in converting revenue into profit. The gross profit margin is stable at 55.25% TTM, suggesting efficient cost management. EBIT and EBITDA margins have improved but remain moderate, indicating potential for operational efficiency gains.

Balance Sheet

The company's debt-to-equity ratio of 0.52 TTM indicates a balanced approach to leveraging, with a manageable level of debt. Return on equity is low at 0.50% TTM, suggesting limited profitability from shareholders' investments. The equity ratio of 54.73% TTM reflects a strong capital structure, providing stability and resilience against financial fluctuations.

Cash Flow

Envista Holdings demonstrates a positive free cash flow growth rate of 1.78% TTM, highlighting effective cash generation. The operating cash flow to net income ratio of 0.37 TTM and free cash flow to net income ratio of 0.87 TTM indicate strong cash flow relative to earnings, although there is room for improvement in cash flow efficiency.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.62B	2.51B	2.57B	2.57B	2.51B	1.93B
Gross Profit	1.45B	1.39B	1.45B	1.49B	1.46B	1.07B
EBITDA	367.90M	279.50M	463.00M	497.70M	496.00M	260.20M
Net Income	15.30M	-1.12B	-100.20M	243.10M	340.50M	33.30M
Balance Sheet
Total Assets	5.64B	5.35B	6.61B	6.59B	6.57B	6.88B
Cash, Cash Equivalents and Short-Term Investments	1.13B	1.07B	940.00M	606.90M	1.07B	888.90M
Total Debt	1.60B	1.55B	1.65B	1.53B	1.48B	1.98B
Total Liabilities	2.55B	2.42B	2.43B	2.38B	2.52B	3.15B
Stockholders Equity	3.09B	2.93B	4.17B	4.21B	4.06B	3.72B
Cash Flow
Free Cash Flow	262.50M	302.70M	217.50M	107.00M	336.70M	236.20M
Operating Cash Flow	300.10M	336.50M	275.70M	182.70M	391.40M	283.90M
Investing Cash Flow	-43.00M	-54.60M	-62.40M	-657.30M	232.90M	-69.10M
Financing Cash Flow	-146.60M	-103.70M	118.90M	12.50M	-465.60M	492.50M

Envista Holdings Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 20.05
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NVST, the sentiment is Positive. The current price of 20.05 is above the 20-day moving average (MA) of 20.02, below the 50-day MA of 20.36, and above the 200-day MA of 19.22, indicating a neutral trend. The MACD of -0.09 indicates Negative momentum. The RSI at 51.94 is Neutral, neither overbought nor oversold. The STOCH value of 42.32 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NVST.

Envista Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NVST	64 Neutral	$3.30B	241.75	0.50%	―	4.73%	―
BLCO	56 Neutral	$5.51B	―	-4.69%	―	6.23%	17.53%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CLOV	50 Neutral	$1.34B	-22.02	-16.90%	―	15.23%	38.79%
ABCL	47 Neutral	$1.17B	―	-16.81%	―	7.16%	3.95%
IRON	43 Neutral	$3.16B	―	-34.78%	―	―	-34.96%
XRAY	39 Underperform	$2.20B	―	-44.44%	5.83%	-7.08%	-113.81%

Envista Holdings Corporate Events

Envista Holdings Reports Strong Q3 2025 Results

Envista Holdings Corporation is a leading global dental products company, offering a comprehensive portfolio of dental consumables, solutions, technology, and services to dental professionals worldwide. The company is known for its strong market positions in attractive segments of the dental industry, supported by its Envista Business System methodology and commitment to innovation.

Envista Holdings Director Resignation Announced

On September 15, 2025, Barbara B. Hulit announced her resignation from the Board of Directors of Envista Holdings Corporation, effective September 26, 2025. Her departure is to pursue another opportunity and is not due to any disagreements with the company’s operations, policies, or practices.

The most recent analyst rating on (NVST) stock is a Hold with a $19.00 price target. To see the full list of analyst forecasts on Envista Holdings stock, see the NVST Stock Forecast page.

Envista Holdings’ Earnings Call: Growth Amid Challenges

Envista Holdings’ recent earnings call painted a balanced picture of the company’s financial health and strategic direction. The call highlighted strong revenue and EPS growth, alongside margin expansion and an updated guidance. However, it also acknowledged challenges such as FX losses, tariff headwinds, and declines in the Chinese market.

Envista Holdings Reports Strong Q2 2025 Growth

Envista Holdings is a leading global dental products company, offering a comprehensive range of dental consumables, solutions, technology, and services to improve patient care. In its second quarter of 2025, Envista Holdings reported significant growth across all its business segments and geographies, leading to an increase in its full-year guidance. The company achieved a sales figure of $682 million, marking a core sales growth of 5.6% compared to the same period last year. Net income for the quarter was $26 million, with an adjusted EBITDA of $84 million, reflecting a 34% increase year-on-year. The adjusted earnings per share rose by 136% to $0.26, showcasing a strong recovery and profitability improvement. Envista’s strategic focus on growth, operations, and employee engagement has contributed to its robust financial performance. The company repurchased 4.8 million shares for approximately $82 million, with $150 million remaining under its stock repurchase program. Looking ahead, Envista’s management remains optimistic, raising its core sales growth guidance for 2025 to 3% to 4%, with an expected adjusted EBITDA margin of around 14%.